{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:32:29Z","timestamp":1754152349239,"version":"3.41.2"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"29","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,18]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Leptomeningeal metastases in pulmonary adenocarcinoma patients carrying epidermal growth factor receptor mutations present a critical therapeutic dilemma. However, there is no established standard therapy following drug resistance. Novel treatment modalities are urgently needed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We report a 62-year-old nonsmoking man who presented with multiple bilateral pulmonary nodules and underwent left lower lobectomy in October 2012.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Pathological examination confirmed poorly differentiated adenocarcinoma with neuroendocrine differentiation, classified as clinical stage IV.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient was initially treated with oral osimertinib; however, resistance developed after 6 months. Genetic analysis revealed an epidermal growth factor receptor exon 21 mutation. After a comprehensive treatment plan that included targeted therapy, radiotherapy, chemotherapy, and concurrent therapies. The patient achieved a total survival time of 28 months following the diagnosis of leptomeningeal metastases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The multimodality treatment method described in this case, incorporating whole-brain radiotherapy, intrathecal chemotherapy (dose escalation), and concurrent therapies, prolonged the patient\u2019s survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Integrating a multimodal treatment plan that includes whole-brain radiotherapy and intrathecal administration of pemetrexed disodium could offer a promising treatment option for lung cancer patients with leptomeningeal metastasis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000043436","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T04:01:03Z","timestamp":1753156863000},"page":"e43436","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Multimodality treatment approach in a patient with EGFR-mutated NSCLC and leptomeningeal metastases: A case report and literature review"],"prefix":"10.1097","volume":"104","author":[{"given":"Long-Hai","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Oncology, Panjin Liaohe Oilfield Gem Flower Hospital, Panjin, Liaoning Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5859-5719","authenticated-orcid":false,"given":"Xin-Xin","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Geriatrics I, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250722","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00432-010-0831-x","article-title":"Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis.","volume":"136","author":"Oechsle","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"R2-20250722","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11060-004-8101-x","article-title":"Leptomeningeal metastases from solid malignancy: a review.","volume":"75","author":"Taillibert","year":"2005","journal-title":"J Neurooncol"},{"key":"R3-20250722","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11060-017-2590-x","article-title":"High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases.","volume":"135","author":"Ge","year":"2017","journal-title":"J Neurooncol"},{"key":"R4-20250722","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/JTO.0b013e3181ce3d1d","article-title":"High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.","volume":"5","author":"Go","year":"2010","journal-title":"J Thorac Oncol"},{"key":"R5-20250722","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study.","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"key":"R6-20250722","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1200\/JCO.2017.75.9589","article-title":"Whole-brain radiotherapy for brain metastases: evolution or revolution?","volume":"36","author":"Brown","year":"2018","journal-title":"J Clin Oncol"},{"key":"R7-20250722","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00432-012-1198-y","article-title":"Effect of chemotherapy on survival after whole brain radiation therapy for brain metastases: a single-center retrospective analysis.","volume":"138","author":"Mayahara","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"key":"R8-20250722","doi-asserted-by":"crossref","first-page":"8267","DOI":"10.1038\/s41598-018-26636-6","article-title":"Metastatic brain tumors disrupt the blood-brain barrier and alter lipid metabolism by inhibiting expression of the endothelial cell fatty acid transporter Mfsd2a.","volume":"8","author":"Tiwary","year":"2018","journal-title":"Sci Rep"},{"key":"R9-20250722","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1200\/JCO.2006.10.0677","article-title":"Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm.","volume":"25","author":"Gerstner","year":"2007","journal-title":"J Clin Oncol"},{"key":"R10-20250722","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12943-018-0778-0","article-title":"Third generation EGFR TKIs: current data and future directions.","volume":"17","author":"Tan","year":"2018","journal-title":"Mol Cancer"},{"key":"R11-20250722","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.21037\/tcr.2018.10.06","article-title":"EGFR first- and second-generation TKIs \u2013 there is still place for them in EGFR-mutant NSCLC patients.","volume":"7","author":"Karachaliou","year":"2018","journal-title":"Transl Cancer Res"},{"key":"R12-20250722","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11060-014-1486-2","article-title":"Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study.","volume":"119","author":"Scott","year":"2014","journal-title":"J Neurooncol"},{"key":"R13-20250722","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1186\/s12885-019-6228-6","article-title":"Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer.","volume":"19","author":"Bazan","year":"2019","journal-title":"BMC Cancer"},{"key":"R14-20250722","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.hemonc.2019.08.008","article-title":"High-dose intravenous methotrexate in the management of breast cancer with leptomeningeal disease: case series and review of the literature.","volume":"12","author":"Kapke","year":"2019","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"R15-20250722","first-page":"2423","article-title":"Interventions to reduce neurological symptoms in patients with GBM receiving radiotherapy: from theory to clinical practice.","volume":"38","author":"Palombi","year":"2018","journal-title":"Anticancer Res"},{"key":"R16-20250722","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer.","volume":"361","author":"Rosell","year":"2009","journal-title":"N Engl J Med"},{"key":"R17-20250722","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.21037\/jtd.2017.07.57","article-title":"Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer.","volume":"9","author":"Li","year":"2017","journal-title":"J Thorac Dis"},{"key":"R18-20250722","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.3747\/co.19.1114","article-title":"Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line.","volume":"19","author":"Leighl","year":"2012","journal-title":"Curr Oncol"},{"key":"R19-20250722","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pharmthera.2016.03.002","article-title":"Overcoming drug resistance to receptor tyrosine kinase inhibitors: learning from lung cancer.","volume":"161","author":"Kuwano","year":"2016","journal-title":"Pharmacol Ther"},{"key":"R20-20250722","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3233\/KCA-190058","article-title":"A review of papillary renal cell carcinoma and MET inhibitors.","volume":"3","author":"Rhoades Smith","year":"2019","journal-title":"Kidney Cancer"},{"key":"R21-20250722","doi-asserted-by":"crossref","first-page":"5839081","DOI":"10.1155\/2018\/5839081","article-title":"The role of combination maintenance with pemetrexed and bevacizumab for advanced stage nonsquamous non-small cell lung cancer: a systematic review and meta-analysis.","volume":"2018","author":"Shan","year":"2018","journal-title":"Biomed Res Int"},{"key":"R22-20250722","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.21037\/tlcr.2019.10.14","article-title":"Mechanisms of resistance to pemetrexed in non-small cell lung cancer.","volume":"8","author":"Liang","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"R23-20250722","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"R24-20250722","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1470-2045(10)70151-0","article-title":"Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.","volume":"11","author":"Crino","year":"2010","journal-title":"Lancet Oncol"},{"key":"R25-20250722","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2014.59.4424","article-title":"BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin\/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer.","volume":"33","author":"Zhou","year":"2015","journal-title":"J Clin Oncol"},{"key":"R26-20250722","doi-asserted-by":"crossref","first-page":"10083","DOI":"10.2147\/CMAR.S222910","article-title":"Bevacizumab in combination with pemetrexed and platinum significantly improved the clinical outcome of patients with advanced adenocarcinoma NSCLC and brain metastases.","volume":"11","author":"Tian","year":"2019","journal-title":"Cancer Manag Res"},{"key":"R27-20250722","doi-asserted-by":"crossref","first-page":"e111475","DOI":"10.1371\/journal.pone.0111475","article-title":"Whole brain radiotherapy plus concurrent chemotherapy in non-small cell lung cancer patients with brain metastases: a meta-analysis.","volume":"9","author":"Qin","year":"2014","journal-title":"PLoS One"},{"key":"R28-20250722","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.ijrobp.2012.11.042","article-title":"A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: radiation Therapy Oncology Group 0320.","volume":"85","author":"Sperduto","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R29-20250722","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/ijc.30214","article-title":"Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: a prospective and single-arm study.","volume":"139","author":"Pan","year":"2016","journal-title":"Int J Cancer"},{"key":"R30-20250722","first-page":"3819","article-title":"Gemcitabine and cisplatin for treatment of lung cancer in vitro and vivo.","volume":"22","author":"Teng","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R31-20250722","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4137\/CMO.S6252","article-title":"Gemcitabine:efficacy in the treatment of advanced stage nonsquamous non-small cell lung cancer.","volume":"5","author":"Hayashi","year":"2011","journal-title":"Clin Med Insights Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T04:01:07Z","timestamp":1753156867000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":31,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043436","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2025,7,18]]}}}